UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1253-8
Program Prior Authorization/Notification
Medication Tavalisse® (fostamatinib disodium hexahydrate)
P&T Approval Date 8/2018, 8/2019, 9/2020, 9/2021, 1/2022, 1/2023, 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Tavalisse (fostamatinib) is a kinase inhibitor indicated for the treatment of thrombocytopenia in
adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient
response to a previous treatment.
2. Coverage Criteriaa:
A. Chronic immune thrombocytopenia (ITP)
1. Initial Authorization
a. Tavalisse will be approved based on both of the following criteria
(1) Diagnosis of chronic immune thrombocytopenia (ITP)
-AND-
(2) Patient has had an insufficient response to a previous treatment (e.g.,
corticosteroids, immunoglobulins, thrombopoietin receptor agonists, splenectomy)
Authorization will be issued for 12 months
2. Reauthorization
a. Tavalisse will be approved based on the following criterion:
(1) Documentation of positive clinical response to Tavalisse therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Tavalisse [package insert]. South San Francisco, CA: Rigel Pharmaceuticals; November 2020.
Program Prior Authorization/Notification – Tavalisse (fostamatinib disodium
hexahydrate)
Change Control
8/2018 New program
8/2019 Annual review with no changes to clinical coverage criteria.
9/2020 Annual review. Removed splenectomy from listing of previous treatment
requirements.
9/2021 Annual review with no changes to clinical coverage criteria. Reference
updated.
1/2022 Revised try/fail criteria to insufficient response.
1/2023 Annual review with no changes to clinical coverage criteria. Added state
mandate.
1/2024 Annual review with no changes to clinical coverage criteria.
1/2025 Annual review. Updated initial authorization to 12 months.
© 2025 UnitedHealthcare Services, Inc.
2